Trial Profile

Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jul 2019 Results of pooled analysis of data from MONCAY and TRULIGHT trials assessing proportion of participants who had no detectable HIV in genital fluids were published in the Clinical Infectious Diseases.
02 Jan 2019 Primary endpoint (Viral Load) has been met, according to the results published in the Clinical Infectious Diseases.
02 Jan 2019 Results published in the Clinical Infectious Diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com